Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203313
'Patent Rights' shall mean (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 6792
During the Term, Licensor grants to Licensee an exclusive, world-wide license under the Patent Rights and the Know-How to develop, make, have made, use, sell, have sold, offer for sale, import or otherwise commercialize Licensed Products and Improvements in the Field. For the avoidance of doubt, the scope of the Licensee Licenses shall extend to Combination Products. Licensee may sublicense the Licensee Licenses to any third party, however, such sublicense(s) shall not relieve Licensee of its obligations to Licensor under this Agreement. Licensee shall promptly inform Licensor of the issuance of all such sublicenses.
Licensor shall promptly deliver to Licensee or provide Licensee with copies of (1) all documents, drawings, specifications, programs, devices and equipment relating to, and all other tangible manifestations of, the Know-How; and (2) all patent applications for which U.S. and international patents have not issued included in the Patent Rights.
(a) U.S. patent application number 12/446,914,
(b) U.S. patent application number 11/804,722,
(c) U.S. patent application number 11/804,720,
(d) Japanese patent application number 2009-511109,
(e) Canadian patent application number 2687118,
(f) U.S. patent application number 11/867,595,
(g) U.S. patent application number 12/535,640
(h) U.S. patent application number 12/535,623
(i) U.S. patent application number 12/517,507,
(j) U.S. patent application number 12/301,223,
(k) E.P.O. patent application number 7,795,135.8,
(l) Japanese patent application number 2009-511110, and
(m) Canadian patent application number 2687124.
IPSCIO Record ID: 211925
The product is the proprietary compound known as ORI-9020. ORI-9020 means ORI-9020 and its analogs, the chemical composition of which are described in the patent and any prodrug, metabolite, analog, salt, hydrate, solvate, polymorph, chimeric or inverted chimeric or isomer of ORI-9020.